医学
间质性肺病
重症监护医学
结缔组织病
免疫抑制
疾病
病理
临床试验
肺
结缔组织
内科学
自身免疫性疾病
作者
Danielle Antin‐Ozerkis,Monique Hinchcliff
标识
DOI:10.1016/j.ccm.2019.05.008
摘要
Interstitial lung disease is common among patients with connective tissue disease and is an important contributor to morbidity and mortality. Infection and drug toxicity must always be excluded as the cause of radiographic findings. Immunosuppression remains a mainstay of therapy despite few controlled trials supporting its use. When a decision regarding therapy initiation is made, considerations include an assessment of disease severity as well as a determination of the rate of progression. Because patients may have extrathoracic disease activity, a multidisciplinary approach is crucial and should include supportive and nonpharmacologic management strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI